Hepatic Safety of IL-17 Inhibitors in Patients With Psoriasis

Panelists discuss how when prescribing an IL-17 inhibitor, key safety considerations include infection risk (particularly tuberculosis and fungal infections), inflammatory bowel disease exacerbation, allergic reactions, neutropenia, immunogenicity, vaccination timing, pregnancy/breastfeeding status, malignancy history, and monitoring requirements for adverse events.